Categorynews

KalVista Pharmaceuticals to Present Data at Upcoming Scientific Conferences

May 20, 2019 Off By BusinessWire

– Phase 1 Data on Oral Plasma Kallikrein Inhibitor KVD900 for
Potential On-Demand Treatment of HAE Attacks to be Presented –

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24KALV&src=ctag" target="_blank"gt;$KALVlt;/agt;–KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, announced that
data has been accepted for presentation at both the C1 Inhibitor
Deficiency and Angioedema Workshop in Budapest, Hungary and European
Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon,
Portugal.

“We are excited to present more Phase 1 data on KVD900, our oral plasma
kallikrein inhibitor in development for on-demand treatment of
hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive
Officer of KalVista. “Our Phase 2 clinical trial of KVD900 is still
expected to have data late this year. We remain committed to providing
options for patients to manage their disease with oral medicines.”

C1 Inhibitor Workshop Presentations:

KVD900, a new oral on-demand treatment of hereditary angioedema
attacks achieves complete plasma kallikrein suppression: safety,
tolerability, pharmacokinetic and pharmacodynamic results from a phase
1 first-in-human study
Saturday, May 25, 2019 from
11:00-12:30 CEST, Oral 25

High plasma exposures of KVD900 achieved in First in Human study
markedly inhibit plasma prekallikrein activation; early blockade of
plasma kallikrein (PKa) may halt attacks in hereditary angioedema
(HAE) by reducing contact system activation
Saturday, May 25,
2019 from 2:30-4:00 pm CEST, Poster 35

EAACI Poster:

Rapid and Nearly Complete Suppression of Plasma Kallikrein Activity
with the Oral Inhibitor KVD900: Results of a Phase 1 Study Evaluating
KVD900’s Potential as a Treatment for Acute Attacks of HAE
Tuesday,
June 4, 2019 from 10:30-12:00 pm WEST
PDS #21, Mediators in
anaphylaxis and angioedema, Zone B

About KalVista Pharmaceuticals, Inc.
KalVista
Pharmaceuticals, Inc. is a pharmaceutical company focused on the
discovery, development, and commercialization of small molecule protease
inhibitors for diseases with significant unmet need. The initial focus
is on inhibitors of plasma kallikrein, which is an important component
of the body’s inflammatory response and which, in excess, can lead to
increased vascular permeability, edema and inflammation. KalVista has
developed a proprietary portfolio of novel, small molecule plasma
kallikrein inhibitors initially targeting hereditary angioedema (HAE)
and diabetic macular edema (DME). The Company has created a structurally
diverse portfolio of oral plasma kallikrein inhibitors and is advancing
multiple drug candidates for HAE as well as DME. The Company has
selected KVD900 as its program to be advanced as an on-demand therapy
for HAE attacks and commenced a Phase 2 proof-of-concept study in HAE
patients in late 2018. In DME, KalVista’s most advanced program, an
intravitreally administered plasma kallikrein inhibitor known as KVD001,
began a Phase 2 clinical trial in 2017 that is anticipated to complete
in the second half of 2019.

For more information, please visit www.kalvista.com.

Forward-Looking Statements
This press release contains
“forward-looking” statements within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by words such as:
“anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,”
“will” and similar references to future periods. These statements are
subject to numerous risks and uncertainties that could cause actual
results to differ materially from what we expect. Examples of
forward-looking statements include, among others, available funding, our
cash runway and future clinical trial timing and results. Further
information on potential risk factors that could affect our business and
its financial results are detailed in the annual report on Form 10-K
filed on July 30, 2018 and other reports as filed from time to time with
the Securities and Exchange Commission. We undertake no obligation to
publicly update any forward-looking statement, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.